Safety and Efficacy of Apixaban Versus Enoxaparin/Warfarin in Patients with Extremes of Body Weight: Post-Hoc Analysis of the AMPLIFY Trial

Blood20.30
Volume: 134, Issue: Supplement_1, Pages: 1152 - 1152
Published: Nov 13, 2019
Abstract
BACKGROUND: Guidelines recommend avoiding direct oral anticoagulants (DOACs) in patients who weigh >120 kg due to limited clinical data in this population. OBJECTIVES: The objective of this post-hoc analysis of the AMPLIFY trial was to evaluate the efficacy, safety, and exposure of apixaban for the treatment of VTE in patients across the following weight categories: ≤ 60 kg, >60 to <100 kg, ≥ 100 to < 120 kg and ≥ 120 kg. METHODS:...
Paper Details
Title
Safety and Efficacy of Apixaban Versus Enoxaparin/Warfarin in Patients with Extremes of Body Weight: Post-Hoc Analysis of the AMPLIFY Trial
Published Date
Nov 13, 2019
Journal
Volume
134
Issue
Supplement_1
Pages
1152 - 1152
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.